The first-ever human Ebola vaccine trial will start next month

The United States will begin the first-ever human trials of an Ebola vaccine, the National Institute for Health announced Tuesday.

The NIH will start a Phase I trial in September with three volunteers who have already enrolled in the experiment. The NIH hopes to expand the trial group to 20 people, and report initial results about the vaccine's efficacy by the end of the year.

The new vaccine was developed in partnership between the federal government and GlaxoSmithKline, one of the world's largest pharmaceutical companies. It comes as the Ebola outbreak shows no sign of abating, with the World Health Organization projecting Thursday morning the virus could infect as many as 20,000 people.

"This public health emergency demands an all-hands-on-deck response," said Anthony Fauci, director of the National Institute of Allergy and Infectious Disease. "We have accelerated the timeline for testing vaccines we have been working on for many years."

No current vaccine or treatment for Ebola currently exists and finding investment to fight the disease — which tends to afflict some of the poorest populations in the world — has been a constant challenge.

"These outbreaks affect the poorest communities on the planet," says Daniel Bausch, an associate professor at Tulane University who has worked on disease outbreaks.  "Although they do create incredible upheaval, they are relatively rare events. So if you look at the interest of pharmaceutical companies, there is not huge enthusiasm to take an Ebola drug through phase one, two, and three of a trial and make an Ebola vaccine that maybe a few tens of thousands or hundreds of thousands of people will use."

The goal of the Ebola vaccine, Faluci said, was to develop a vaccine that could be used to immunize those who are at high risk of catching the disease, like health care workers,  and also communities that are facing an outbreak situation.

The NIH did not provide any estimate of when the the testing would be completed or when the vaccine could be available for more widespread use. Phase I is only the first step in the drug-approval process. It's the phase where drug companies test whether a drug is safe — that it doesn't create dangerous complications or side effects — before larger studies look at whether the drug actually works.

Will you support Vox’s explanatory journalism?

Most news outlets make their money through advertising or subscriptions. But when it comes to what we’re trying to do at Vox, there are a couple of big issues with relying on ads and subscriptions to keep the lights on:

First, advertising dollars go up and down with the economy. We often only know a few months out what our advertising revenue will be, which makes it hard to plan ahead.

Second, we’re not in the subscriptions business. Vox is here to help everyone understand the complex issues shaping the world — not just the people who can afford to pay for a subscription. We believe that’s an important part of building a more equal society. And we can’t do that if we have a paywall.

So even though advertising is still our biggest source of revenue, we also seek grants and reader support. (And no matter how our work is funded, we have strict guidelines on editorial independence.)

If you also believe that everyone deserves access to trusted high-quality information, will you make a gift to Vox today? Any amount helps.

One-Time Monthly Annual

$5/month

$10/month

$25/month

$50/month

Other

$

Yes, I'll give $5/month

Yes, I'll give $5/month

We accept credit card, Apple Pay, and Google Pay. You can also contribute via